21 avr. Hématome sous dural chronique bilatéral compliquant une dérivation ventriculo- péritonéale. Bilateral chronic subdural hematoma. a prospective randomized study. Traitement par corticoïdes des hématomes sous-duraux chroniques: une étude prospective randomisée. Hématome sous dural chronique. Motif d’hostitalisation. Mme M 70 ans. Admise en urgence pour: aphasie hemiparésie droite. Histoire de la.

Author: Fenrilkis Godal
Country: Myanmar
Language: English (Spanish)
Genre: Science
Published (Last): 27 July 2012
Pages: 335
PDF File Size: 15.62 Mb
ePub File Size: 8.51 Mb
ISBN: 948-8-26347-415-8
Downloads: 47281
Price: Free* [*Free Regsitration Required]
Uploader: Mukasa

Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer AND drug name.

Pneumonia AND sponsor name. How to search [pdf]. For these items you should use the filters and not add them to your search terms in the text field. Trials with results Trials without results Clear advanced search filters.

Hématome sous-dural chronique et décompensation psychotique – EM|consulte

Review by the Competent Authority or Ethics Committee in the country concerned. EU Clinical Trials Register. Both Female Only Male Only. IMP with orphan designation in the indication.


Trials with results Trials without results. Clear advanced search filters.

Date on which this record was first entered in the EudraCT database:. Treatment of chronic subdural hematoma by corticosteroids: Title of the trial for lay people, in easily understood, i.

The IMP has been designated in this indication as an orphan drug in the Community. Committee on Advanced therapies CAT has issued a classification for this product.

Combination product that includes a device, but does not involve an Advanced Therapy. The trial involves single site in the Member State concerned. Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.